What's Happening?
The Health Resources and Services Administration (HRSA) has announced a revised 340B Rebate Model Pilot Program, which will require participating manufacturers to provide 340B pricing through rebates instead of upfront discounts for certain drugs selected
for the Medicare Drug Price Negotiation Program's 2026 and 2027 price applicability years. This move follows a decision by the D.C. Circuit in Novartis v. Kennedy, which confirmed that rebate models are permissible under Section 340B but require approval from the Department of Health and Human Services (HHS). The revised pilot aims to address concerns about duplicate discounts and provide better visibility into individual transactions. Eligible manufacturers must submit rebate plans by August 24, 2026, with the program set to take effect on January 1, 2027.
Why It's Important?
The revised 340B Rebate Pilot Program is significant as it represents HRSA's effort to adapt to the growing complexity and size of the 340B Program, which has reached over $100 billion in purchases at discounted pricing. The shift to a rebate model is intended to prevent duplicate discounts, a concern heightened by the Medicare Drug Price Negotiation Program. This change could impact manufacturers, covered entities, and the broader healthcare market by altering how drug pricing and discounts are managed. The program's success or failure could influence future policy decisions and legislative actions regarding drug pricing and healthcare cost management.
What's Next?
The implementation of the revised pilot will be closely watched by stakeholders, including manufacturers, healthcare providers, and policymakers. The American Hospital Association has expressed concerns about the compliance and operational burdens the model may impose on covered entities. Meanwhile, Congress is considering various legislative proposals that could affect the future of the 340B Program, including the SECURE 340B Act and the SUSTAIN 340B Act. The outcome of these legislative efforts, along with potential judicial reviews, will determine the long-term viability and structure of the rebate model.
